Specialty Pharmacy

During a study investigating therapeutics that target how RNA splicing activates antiviral immune pathways in triple-negative breast cancers, researchers observed that endogenous RNA in tumor cells that had been mis-spliced is able to mimic an RNA virus.

Study finds that recurring glioblastoma tumors with very few mutations respond significantly better to immunotherapies than similar tumors with multiple mutations.

Nonadherence is linked to poor health outcomes, including a decreased quality-of-life, disease progression, and increased hospitalizations.

The study findings emphasize the need for people who missed or postponed a cancer screening test early in the pandemic to contact their health care provider to discuss the potential need to reschedule it, according to the study authors.

FDA grant priority review to a supplemental biologics license application for nivolumab (Opdivo) for use as an adjuvant treatment for patients with resected esophageal or gastroesophageal junction cancer.

Obstacles to cancer screenings for low-income patients can include lack of transportation and an inability to take time off of work.

Pharmacists can learn how to adequately inform patients about therapeutic options that are available as a method to improve access to care.

Narsoplimab is an investigational, fully human IgG4 monoclonal antibody was designed to bind to mannan-binding lectin-associated serine protease-2

A minimally invasive, targeted treatment option, ImPACT is also under evaluation in patients with other localized tumors, such as urothelial cancer, esophageal cancer, lung cancer, and pancreatic cancer.

The FDA approved Enhertu in January 2020 for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.

The right balance of stem cell dose, cell type, and timing of antiretroviral therapy (ART) could potentially lead to a spontaneous cure of HIV, according to the study authors.

Daratumumab and hyaluronidase-fihj, a subcutaneous formulation of daratumumab, is the first FDA-approved treatment for patients with AL amyloidosis.

A survey found that the majority of oncologists did not feel like they could perform their duties as well as they could prior to the COVID-19 pandemic.

Crizotinib is the first biomarker-driven therapy for relapsed or refractory anaplastic large cell lymphoma in children and young adults.

Novel program found cost effective and safe for patients with cancer managing the adverse effects of treatment.

As new testing devices, therapies, and vaccines are approved for COVID-19, patients will be dependent on their health care providers for answers and education.

Although only a proportion of DCIS cases will progress into invasive cancer, the treatments available for DCIS are similar to treatments for invasive breast cancers.

The FDA has granted an orphan drug designation to the BCMA-targeted trispecific T-cell activating recombinant protein construct as treatment for patients with multiple myeloma.

Study finds the COVID-19 pandemic has drastically improved the quality and convenience of virtual cancer care.

According to research conducted at Rush University Medical Center, opioid use may increase patients’ risk of developing pancreatic cancer.

The current study provides characterization of a lipid-rich necrotic core, a dangerous type of coronary plaque made up of dead cells and cell debris that is prone to rupture, which can lead to a heart attack or stroke.

The FDA has granted fast track designations to cavrotolimod (AST-008) for use in combination with a PD-1 therapy in patients with locally advanced or metastatic Merkel cell carcinoma.

The Association of Community Cancer Centers offers virtual learning series.

Pvsripo is a novel immunotherapy that activates patients’ innate and adaptive immune system to enable anti-tumor response and establish immunologic memory to prevent the recurrence of cancer.

A significantly greater proportion of patients with Crohn disease achieved both primary endpoints with overall safety results generally consistent with the known safety profile of risankizumab.

Darolutamide led to a 31% reduction in the risk of death, extending survival for patients with non-metastatic prostate cancer.

Pralatrexate, a lymphoma drug, outperformed remdesivir in treating COVID-19 in a lab experiment.

According to the study authors, this could lead to finding the exact molecular trigger and gives hope for developing a targeted PsA treatment in the future.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the treatment considerations necessary to properly manage a patient with congenital plasminogen deficiency after she became pregnant.

FDA approves request submitted by Moleculin Biotech, Inc. for rare disease designations to be granted their drug candidate that appears to directly elicit tumor cell death and prompt the immune system to eliminate tumors.